Clinical Trials Browser

Recurrence × Docetaxel × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02460367 2022-04-06

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Phase 1 Terminated

16 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01774578 2020-05-28

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Phase 2/3 Terminated

135 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

NCT02346370 2019-02-08

PRIMAL

Phase 1 Terminated

16 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00378404 2015-06-08

Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC

Phase 1 Terminated

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Recurrence

NCT00095199 2012-10-15

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Phase 3 Completed

939 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00356122 2011-10-17

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

53 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

CCODG-NSCLC

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

PRIMAL

Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)